Literature DB >> 15743202

Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors.

Philip A Harris1, Mui Cheung, Robert N Hunter, Matthew L Brown, James M Veal, Robert T Nolte, Liping Wang, Wendy Liu, Renae M Crosby, Jennifer H Johnson, Andrea H Epperly, Rakesh Kumar, Deirdre K Luttrell, Jeffrey A Stafford.   

Abstract

A series of derivatives of 2-anilino-5-phenyloxazole (5) has been identified as inhibitors of VEGFR2 kinase. Herein we describe the structure-activity relationship (SAR) of this novel template. Optimization of both aryl rings led to very potent inhibitors at both the enzymatic and cellular levels. Oxazole 39 had excellent solubility and good oral PK when dosed as the bis-mesylate salt and demonstrated moderate in vivo efficacy against HT29 human colon tumor xenografts. X-ray crystallography confirmed the proposed binding mode, and comparison of oxazoles 39 and 46 revealed interesting differences in orientation of 2-pyridyl and 3-pyridyl rings, respectively, attached at the meta position of the 5-phenyl ring.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15743202     DOI: 10.1021/jm049538w

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  27 in total

1.  A combinatorial in silico and cellular approach to identify a new class of compounds that target VEGFR2 receptor tyrosine kinase activity and angiogenesis.

Authors:  J Kankanala; A M Latham; A P Johnson; S Homer-Vanniasinkam; C W G Fishwick; S Ponnambalam
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

2.  Synthesis and biological activity of N(4)-phenylsubstituted-6-(2,4-dichloro phenylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic and antitumor agents.

Authors:  Aleem Gangjee; Sonali Kurup; Michael A Ihnat; Jessica E Thorpe; Satyendra S Shenoy
Journal:  Bioorg Med Chem       Date:  2010-03-27       Impact factor: 3.641

3.  Mechanistic Insight Leads to a Ligand Which Facilitates the Palladium-Catalyzed Formation of 2-(Hetero)Arylaminooxazoles and 4-(Hetero)Arylaminothiazoles.

Authors:  Esben P K Olsen; Pedro L Arrechea; Stephen L Buchwald
Journal:  Angew Chem Int Ed Engl       Date:  2017-07-24       Impact factor: 15.336

4.  Evolution of a New Class of VEGFR-2 Inhibitors from Scaffold Morphing and Redesign.

Authors:  Nello Mainolfi; Rajeshri Karki; Fang Liu; Karen Anderson
Journal:  ACS Med Chem Lett       Date:  2016-02-02       Impact factor: 4.345

5.  Novel VEGFR-2 kinase inhibitors identified by the back-to-front approach.

Authors:  Kingkan Sanphanya; Suvara K Wattanapitayakul; Suwadee Phowichit; Valery V Fokin; Opa Vajragupta
Journal:  Bioorg Med Chem Lett       Date:  2013-03-20       Impact factor: 2.823

6.  Quinoides and VEGFR2 TKIs influence the fate of hepatocellular carcinoma and its cancer stem cells.

Authors:  Deniz Cansen Kahraman; Gilles Hanquet; Loïc Jeanmart; Steve Lanners; Peter Šramel; Andrej Boháč; Rengul Cetin-Atalay
Journal:  Medchemcomm       Date:  2016-10-07       Impact factor: 3.597

7.  Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer.

Authors:  Neng Wang; Zhi-Yu Wang; Sui-Lin Mo; Tjing Yung Loo; Dong-Mei Wang; Hai-Bin Luo; De-Po Yang; Yu-Ling Chen; Jian-Gang Shen; Jian-Ping Chen
Journal:  Breast Cancer Res Treat       Date:  2012-02-21       Impact factor: 4.872

8.  (1S*,4'S*,5R*)-1-Isobutyl-5-meth-oxy-2',3-dimethyl-4,6-dioxa-2-aza-spiro-[bicyclo-[3.2.0]hept-2-ene-7,4'-isoquinoline]-1',3'(2'H,4'H)-dione.

Authors:  Hoong-Kun Fun; Ching Kheng Quah; Chengmei Huang; Haitao Yu
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2011-04-29

9.  Synthesis of 5-(ethylsulfonyl)-2-methoxyaniline: An important pharmacological fragment of VEGFR2 and other inhibitors.

Authors:  Miroslav Murár; Gabriela Addová; Andrej Boháč
Journal:  Beilstein J Org Chem       Date:  2013-01-25       Impact factor: 2.883

10.  Profile of the GSK published protein kinase inhibitor set across ATP-dependent and-independent luciferases: implications for reporter-gene assays.

Authors:  Patricia Dranchak; Ryan MacArthur; Rajarshi Guha; William J Zuercher; David H Drewry; Douglas S Auld; James Inglese
Journal:  PLoS One       Date:  2013-03-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.